

Supplementary tables:

Supplementary Table 1: Guidance on anticoagulants, antiplatelets and other medications affecting coagulation prior to percutaneous kidney biopsy

7 days prior to percutaneous kidney biopsy*	5 days prior to percutaneous renal biopsy⁺	72 hours prior to percutaneous kidney biopsy⁺	24 hours prior to percutaneous kidney biopsy	6 hours prior to percutaneous kidney biopsy
Withhold aspirin, clopidogrel, ticagrelor, omega-3-fatty acids (e.g. krill oil, fish oil)	Withhold warfarin	Withhold direct oral anticoagulants (e.g. apixaban, rivaroxaban, dabigatran)	Withhold low molecular weight heparin (e.g. enoxaparin), No non-steroidal anti-inflammatories	Withhold unfractionated heparin infusion

* Decision regarding continuation of aspirin in patients at high risk for a cardiovascular event (i.e. within 3 months of bare metal coronary stent or 12 months of drug eluted stent, symptomatic myocardial ischemia, previous ischaemic stroke and peripheral vascular disease including peripheral stent) were individualised (risks vs. benefits). Non-urgent biopsies within 3 months of bare metal coronary stent or 12 months of drug eluted stent were delayed whenever appropriate.

⁺ Bridging anticoagulation was indicated in patients with mechanical mitral valve, mechanical aortic valve and additional stroke risk factors such as antiphospholipid syndrome, an embolic event within 3 months or a previous thromboembolic event with interruption of anticoagulation.

Supplementary Table 2: Odds ratios (OR) and 95% confidence intervals (CIs) for the association between potential predictors and bleeding complications in native kidney biopsies

Characteristics	Minor Bleeding Events	Major Bleeding Events	
	Unadjusted OR (95% CI)	Unadjusted (95% CI)	Adjusted OR (95% CI)
Age	0.97 (0.94-1.00)	1.04 (1.00-1.08)	1.03 (0.99-1.07)
Gender			
Male	Ref	Ref	Ref
Female	7.29 (1.58-33.73)	13.26 (1.67-105.49)	9.52 (1.15-78.60)
Systolic BP			
<140	Ref	Ref	
140-150	1.17 (0.30-4.58)	0.44 (0.05-3.71)	-
151-160	2.55 (0.28-23.35)	5.84 (1.02-33.42)	-
>160	-	5.11 (0.50-51.91)	-
Diastolic BP			
<80	Ref	Ref	
80-90	1.43 (0.34-5.90)	0.36 (0.07-1.73)	-
91-100	-	-	-

>100	-	-	-
Needle gauge			
16	Ref	Ref	
18	0.69 (0.09-5.56)	-	-
Number of passes	0.91 (0.47-1.78)	0.94 (0.45-1.93)	-
Creatinine	1.00 (0.99-1.00)	1.00 (0.99-1.00)	-
Hemoglobin	0.98 (0.96-1.01)	0.95 (0.91-0.98)	0.96 (0.92-1.00)
Median uACR	0.99 (0.99-1.00)	0.99 (0.99-1.00)	-
KRT			
No	Ref	Ref	Ref
Yes	1.48 (0.18-12.48)	6.68 (1.55-28.75)	2.04 (0.31-13.47)
DDAVP			
No	Ref	Ref	Ref
Yes	1.06 (0.32-3.59)	4.19 (1.18-14.83)	1.41 (0.30-6.54)

uACR: urine albumin:creatinine ratio; KRT: Kidney replacement therapy

Supplementary Table 3: Descriptive characteristics of female patients according to minor and major bleeding events (N=140)

Characteristics	Total N=140 N (%)	No bleeding complications N=118 N (%)	Minor bleeding events (hematuria, hematoma) N=12 N (%)	Major bleeding events (blood products, admission to ICU or intervention) N=10 N (%)	P-value
Age (Mean, SD)	51.1 (17.7)	51.2 (17.6)	41.4 (13.9)	61.8 (18.4)	0.0258
Native/Transplant					
Native	137 (40.4)	115 (97.5)	12 (100.0)	10 (100.0)	0.751
Transplant	3 (0.9)	2 (2.5)	0	0	
If Native, which side					0.281
Left	94 (86.2)	77 (87.5)	10 (90.9)	7 (70.0)	
Right	15 (13.8)	11 (12.5)	1 (9.1)	3 (30.0)	
Inpatient/Outpatient					0.632
Inpatient	129 (92.1)	108 (91.5)	11 (91.7)	10 (100.0)	
Outpatient	11 (7.9)	10 (8.5)	1 (8.3)	0	
Systolic BP					0.068
<140	90 (67.2)	77 (68.1)	7 (63.6)	6 (60.0)	

140-150	35 (26.1)	30 (26.6)	4 (36.4)	1 (10.0)	
151-160	7 (5.2)	5 (4.4)	0	2 (20.0)	
>160	2 (1.5)	1 (0.9)	0	1 (10.0)	
Diastolic BP					0.747
<80	70 (59.3)	59 (57.8)	4 (57.1)	7 (77.8)	
80-90	43 (36.4)	38 (37.3)	3 (42.9)	2 (22.2)	
91-100	5 (4.2)	5 (4.9)	0	0	
Creatinine (Median, IQR)	146.5 (94-219.5)	141 (95-214)	139 (87-294.5)	230.5 (128-369)	0.663
Urea (Median, IQR)	10.5 (6.9-14.3)	10.4 (6.9-14.0)	9.1 (5.8-13.3)	12.6 (10.5-19.1)	0.131
Hemoglobin (Mean, SD)	111.2 (20.1)	112.1 (19.4)	113.6 (21.7)	97 (23.3)	0.066
Platelets (Mean, SD)	293.4 (105.1)	295.1 (92.4)	256.7 (85.9)	318 (218.5)	0.363
INR (Median, IQR)	1 (0.9-1.1)	1 (0.9-1.1)	1 (0.9-1.1)	1.1 (1-1.2)	0.354
aPTT (Mean, SD)	27.6 (4.0)	27.5 (4.0)	27.4 (2.5)	29 (5.2)	0.526
Median uACR (Median, IQR)	68.4 (5.1-231.5)	48.8 (4.9-224)	121.5 (18.5-211)	200 (31.6-234)	0.455
Kidney replacement therapy					0.013
No	130 (92.9)	112 (94.9)	11 (91.7)	7 (70.0)	
Yes	10 (7.1)	6 (5.1)	1 (8.3)	3 (30.0)	

DDAVP					0.123
No	96 (68.6)	83 (70.3)	9 (75.0)	4 (40.0)	
Yes	44 (31.4)	35 (29.7)	3 (25.0)	6 (60.0)	
Needle gauge					0.516
16	123 (36.3)	103 (88.0)	11 (91.7)	9 (100.0)	
18	15 (4.4)	14 (12.0)	1 (8.3)	0	
Number of passes (Median, IQR)	2 (2-3)	2 (2-3)	2 (2-3.5)	2.5 (2-3)	0.801
Number of cores (Mean, SD)	2.0 (0.7)	1.9 (0.7)	2.1 (0.7)	1.9 (1.0)	0.811

p-values are based on chi-squared for categorical data, ANOVA for normally distributed variables when comparing three groups, K-sample equality of medians test for non-normally distributed variables.

Supplementary Table 4: Odds ratios (OR) and 95% confidence intervals for the association between potential predictors and bleeding complications in females.

Characteristics	Minor bleeding events (hematuria, hematoma)		Major bleeding events (blood products, admission to ICU or intervention)	
	Unadjusted OR (95% CI)	Adjusted OR (95% CI)	Unadjusted (95% CI)	Adjusted OR (95% CI)
DDAVP				
No	Ref		Ref	
Yes	0.79 (0.20-3.10)	-	3.56 (0.65-13.39)	-
Age	0.97 (0.93-1.00)	-	1.04 (0.99-1.08)	-

Systolic BP				
<140	Ref		Ref	
140-150	1.47 (0.40-5.38)	-	0.43 (0.05-3.70)	-
151-160	-	-	5.13 (0.82-32.27)	-
>160	-	-	12.83 (0.71-231.75)	-
Diastolic BP				
<80	Ref		Ref	
80-90	1.16 (0.25-5.49)	-	0.44 (0.09-2.25)	-
91-100	-	-	-	-
Needle gauge				
16	Ref		Ref	
18	0.67 (0.08-5.58)	-	-	-
Number of passes	1.26 (0.68-2.34)	-	1.20 (0.59-2.42)	-
Creatinine	1.00 (1.00-1.00)	-	1.00 (1.00-1.00)	-
Hemoglobin	1.00 (0.97-1.04)	-	0.96 (0.92-0.99)	0.97 (0.93-1.01)
Median uACR	1.00 (1.00-1.00)	-	1.00 (1.00-1.00)	-
Kidney replacement therapy				
No	Ref		Ref	Ref

Yes	1.70 (0.19-15.40)	-	8 (1.64-38.93)	3.83 (0.62-23.56)
Number of Aspirin taken	-	-	-	-
Taken Aspirin				
No	Ref			
Yes	1.71 (0.21-14.08)	-	-	-

Supplementary Table 5: Break down of the type of kidney tissue present in the histology between males and females

Kidney tissue samples*	Male N (%)	Females N (%)
Medulla	3 (2)	1 (0.7)
Cortex	69 (47.5)	66 (47.1)
Medulla and Cortex	72 (49.1)	72 (51.4)
Non kidney tissue	1 (0.7)	1 (0.7)

*Fisher's exact test p-value=0.862